Oral dosage forms including an antiplatelet agent and an enterically coated acid inhibitor
AssigneeAG Acquisition Corporation
InventorsMark Goldsmith, Elizabeth B. Vadas
Life of this patent
Estimating the term…
Abstract
The present disclosure provides oral dosage forms comprising an antiplatelet agent and an enterically coated acid inhibitor, as well as methods of treating subjects with an antiplatelet agent and an enterically coated acid inhibitor.
Claims54
A method of treating a patient who is in need of an antiplatelet agent and does not have symptoms of gastrointestinal bleeding or a gastrointestinal ulcer comprising orally administering to said patient a unit dosage form comprising an effective amount of an antiplatelet agent to inhibit platelet aggregation and an effective amount of a proton pump inhibitor to reduce the risk of developing a gastrointestinal disorder associated with said antiplatelet agent, wherein the proton pump inhibitor is within an enteric coated formulation comprising (a) a core material comprising the proton pump inhibitor;
- and (b) an outer enteric coating.
A method of treating a patient who is in need of an antiplatelet agent and does not have symptoms of gastrointestinal bleeding or a gastrointestinal ulcer comprising orally administering to said patient a unit dosage form comprising an effective amount of an antiplatelet agent to inhibit platelet aggregation and an effective amount of a proton pump inhibitor to reduce the risk of developing a symptom of gastrointestinal bleeding or a gastrointestinal ulcer, wherein the proton pump inhibitor is within an enteric coated formulation comprising (a) a core material comprising the proton pump inhibitor;
- and (b) an outer enteric coating.
A method of treating a patient who is receiving a nonsteroidal anti-inflammatory drug to inhibit platelet aggregation and does not have symptoms of gastrointestinal bleeding or a gastrointestinal ulcer comprising orally administering to said patient a unit dosage form comprising an effective amount of an antiplatelet agent to inhibit platelet aggregation and an effective amount of a proton pump inhibitor to reduce the risk of developing a gastrointestinal disorder associated with said antiplatelet agent, wherein the proton pump inhibitor is within an enteric coated formulation comprising (a) a core material comprising the proton pump inhibitor;
- and (b) an outer enteric coating.
A method of treating a patient who is receiving a nonsteroidal anti-inflammatory drug to inhibit platelet aggregation and does not have symptoms of gastrointestinal bleeding or a gastrointestinal ulcer comprising orally administering to said patient a unit dosage form comprising an effective amount of an antiplatelet agent to inhibit platelet aggregation and an effective amount of a proton pump inhibitor to reduce the risk of developing a symptom of gastrointestinal bleeding or a gastrointestinal ulcer, wherein the proton pump inhibitor is within an enteric coated formulation comprising (a) a core material comprising the proton pump inhibitor;
- and (b) an outer enteric coating.
An oral unit dosage form comprising an antiplatelet agent and a proton pump inhibitor wherein the dosage form is free of a nonsteroidal anti-inflammatory drug, and wherein the proton pump inhibitor is within an enteric coated formulation comprising (a) a core material comprising the proton pump inhibitor;
- and (b) an outer enteric coating.
Dependencies are inferred from the claim text.